Verrica launches underwritten public offering of common stock and warrants

Verrica Pharmaceuticals Inc.

Offering of common stock (or pre-funded warrants) and accompanying warrants; Jefferies sole bookrunner; 30-day option for 15% additional.
Terminated ATM equity prospectus; no shares had been issued under the Open Market Sales Agreement with Jefferies.
Targeting monthly operating cash flow break-even in H2 2025 after restructuring sales force from 80 to ~33 territories.
Phase 2 data for VP-315 in BCC: 86% tumor size reduction, 51% complete histological clearance (n=90); End-of-Phase 2 meeting planned H1 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.